title: Tablet and oral liquid L-thyroxine formulation in the treatment of naïve hypothyroid patients with Helicobacter pylori infection.
abstract: To compare the clinical efficacy of tablet and oral liquid L-thyroxine (LT4) formulation in naïve hypothyroid subjects with Helicobacter pylori infection. Forty-seven adult naïve hypothyroid subjects with dyspeptic symptoms were investigated with upper endoscopy and divided into: 28 patients with Helicobacter pylori infection (Group A); 15 patients without gastric alterations (group B); 4 patients with autoimmune gastritis were excluded from the study. Subjects were randomly treated with a same dose of LT4 tablet (TAB) or oral liquid formulation (SOL), for 9 months on group A and 6 months on group B. Helicobacter pylori infection was eradicated after 3 months of LT4 treatment. On group A, after 3 months (before Helicobacter pylori eradication), subjects treated with SOL showed a greater thyroid-stimulating hormone reduction (ΔTSH3-0: TAB = -4.1 ± 4.6 mU/L; SOL = -7.7 ± 2.5 mU/L; p = 0.029) and a greater homogeneity in the thyroid-stimulating hormone values (TSH3mo: TAB = 5.7 ± 4.9 mU/L; SOL = 4.1 ± 2.0 mU/L; p = 0.025), compared to LT4 tablet. At 9 months (after 6 months of Helicobacter pylori eradication) mean thyroid-stimulating hormone values were lower in subjects treated with LT4 tablet (TSH9mo: TAB = 1.8 ± 1.2 mU/L; SOL = 3.2 ± 1.7 mU/L; p = 0.006). On group B no difference were observed, at each time point, in the mean thyroid-stimulating hormone values and thyroid-stimulating hormone variations between two LT4 formulations. LT4 liquid formulation may produce a better clinical response compared to the tablet formulation in hypothyroid subjects with Helicobacter pylori infection.
authors.affiliation: Division of Endocrinology (DE), Department of Medical & Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, 40126, Bologna, Italy. daniloribichini@yahoo.it.
authors.forename: Danilo
authors.initials: D
authors.lastname: Ribichini
authors.affiliation: Division of Internal Medicine (IM), Department of Medical & Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, 40126, Bologna, Italy.
authors.forename: Giulia
authors.initials: G
authors.lastname: Fiorini
authors.affiliation: Division of Endocrinology (DE), Department of Medical & Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, 40126, Bologna, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Repaci
authors.affiliation: Division of Internal Medicine (IM), Department of Medical & Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, 40126, Bologna, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Castelli
authors.affiliation: Gastroenterogy & Endoscopy Unit, Versilia Hospital, Azienda USL Toscana Nord Ovest, Lido di Camaiore, Italy.
authors.forename: Luigi
authors.initials: L
authors.lastname: Gatta
authors.affiliation: Division of Internal Medicine (IM), Department of Medical & Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, 40126, Bologna, Italy.
authors.forename: Dino
authors.initials: D
authors.lastname: Vaira
authors.affiliation: Division of Endocrinology (DE), Department of Medical & Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, 40126, Bologna, Italy. renato.pasquali@unibo.it.
authors.forename: Renato
authors.initials: R
authors.lastname: Pasquali
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D005260:Female; D005756:Gastritis / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology; D016480:Helicobacter pylori / Q000187:drug effects / Q000502:physiology*; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000378:metabolism; D012720:Severity of Illness Index; D013607:Tablets; D013961:Thyroid Gland / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D013607:Tablets; D013972:Thyrotropin; D013974:Thyroxine
keywords: Dispepsia; Helicobacter pylori; Hypothyroidism; L-thyroxine